Back to homepage

Neurology

Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations

Authors: Jungjin Kim, Eric MacMaster, Thomas L Schwartz

Tardive dyskinesia (TD) can be a disfiguring side-effect of antipsychotic medications. In this article the authors review the risk of TD, the potential etiologic mechanisms and present some interesting cases of patients taking atypical antipsychotics who developed TD.

More

Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon

Authors: Thomas L Schwartz, Viral Goradia

In this article, the authors explore basic sleep physiology, the mechanism of action for each class of hypnotic drugs and their clinical application. The potential pharmacologic sleep-inducing mechanisms of future hypnotics are also described and discussed.

More

Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non-Western countries

Authors: Murat Altin, Ahmed A El-Shafei, Maria Yu, Durisala Desaiah, Tamas Treuer, Nikolay Zavadenko, Hong Yun Gao

This prospective, observational, non-interventional study conducted in six non-Western countries concludes that after 12 months of treatment, clinical and functional outcomes were improved in children and adolescents with attention deficit hyperactivity disorder (ADHD) who initiated and remained on their prescribed pharmacological monotherapy.

More

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary

Authors: Susan G Ball, Durisala Desaiah, Qi Zhang, Michael E Thase, David G S Perahia

Major depressive disorder (MDD) is a significant public health concern and challenges health care providers to intervene with appropriate treatment. This review provides evidence that duloxetine 60 mg QD is effective for the treatment of adult patients with MDD in the short- and long-term phases of treatment. Duloxetine 60 mg QD also represents a viable choice of treatment for those patients with painful physical symptoms associated with MDD.

More